To the Editor: Worldwide, pre-eclampsia is a leading cause of maternal death, affecting 3% to 5% of all pregnancies.
) and exclusion criteria for both groups (history of renal, cardiac, metabolic [diabetic] , or autoimmune disease) were assessed by the enrolling physicians. The study was approved by the ethics committee of the Universidad Autó noma de Bucaramanga, Colombia, and all women enrolled provided written informed consent. Plasma concentrations of ADMA, symmetric dimethylarginine, and L-arginine were measured blinded (within-assay and betweenassay variations for ADMA, 1.7% and 2.5%, respectively; limit of detection, 0.004 µmol/L) by minor modifications of an established method. 4 Our sample size had a greater than 93% power to detect a 40% difference in plasma ADMA concentrations, with PϽ.05 (2-sided) used to determine statistical significance. Results. We found no significant differences in plasma ADMA concentrations among Colombian women with pre-eclampsia (TABLE 2) Comment. Several possible explanations could be considered for this unexpected finding. It is unlikely that the study was underpowered, as it included the largest number of cases reported to our knowledge. Timing of blood sampling (third tri- Abbreviations: ADMA, asymmetric dimethylarginine; CI, confidence interval; NA, not applicable; SDMA, symmetric dimethylarginine. mester at delivery), severity of pre-eclampsia, gestational age at delivery, and birth weight (Table 1) were comparable with those from previous studies from Western Europe. 2, 3, 5 In light of the lack of ethnicity-related differences in ADMA concentrations in our sample, ethnicity does not appear to explain our results.
Thus, our results support the hypothesis that preeclampsia in low-and high-risk populations may have distinct underlying causes.
